Detailed vismodegib data unveiled

Genentech Inc. reported additional data from the pivotal Phase II ERIVANCE BCC trial of oral vismodegib in 104 patients with inoperable advanced basal cell carcinoma. A once-daily 150 mg oral dose of the compound produced an overall response rate (ORR) of 43% in 71 patients with locally advanced BCC (laBCC) and 30% in 33 patients with metastatic BCC (mBCC) as assessed by independent review, which was the trial's primary endpoint. Genentech previously reported that vismodegib met the primary endpoint of ORR in an undisclosed, pre-defined percentage of patients.

As determined by study investigators, ORRs were 60% and 46% for laBCC and mBCC patients, respectively. The median progression-free survival (PFS) for both groups was 9.5 months, as assessed by independent review. Genentech will present the data from the open-label, single-arm, international study on Tuesday at the European Association of Dermato-Oncology meeting in Nantes. ...